Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.30 USD
-0.02 (-1.52%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Marinus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 150 | 241 | 123 | 140 | 92 |
Receivables | 4 | 6 | 3 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 5 | 6 | 5 | 2 |
Total Current Assets | 165 | 252 | 132 | 146 | 94 |
Net Property & Equipment | 4 | 4 | 3 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 3 | 2 | 2 |
Total Assets | 171 | 260 | 137 | 150 | 99 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 12 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 3 | 2 | 3 |
Current Portion Long-Term Debt | 2 | 1 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 23 | 20 | 16 | 9 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 21 | 0 | 0 |
Total Current Liabilities | 41 | 25 | 41 | 11 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 95 | 101 | 41 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 18 | 18 | 2 | 3 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 154 | 144 | 83 | 13 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 4 | 4 | 4 | 28 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 589 | 542 | 460 | 445 | 295 |
Retained Earnings | -572 | -431 | -411 | -312 | -236 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17 | 116 | 53 | 137 | 88 |
Total Liabilities & Shareholder's Equity | 171 | 260 | 137 | 150 | 99 |
Total Common Equity | 17 | 112 | 49 | 133 | 60 |
Shares Outstanding | 54.50 | 49.60 | 36.70 | 30.50 | 20.50 |
Book Value Per Share | 0.31 | 2.26 | 1.34 | 4.35 | 2.91 |
Fiscal Year End for Marinus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 65 | 113 | 150 | 176 | 175 |
Receivables | 3 | 4 | 4 | 4 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 6 | 2 | 3 | 3 |
Other Current Assets | 9 | 9 | 9 | 12 | 11 |
Total Current Assets | 82 | 131 | 165 | 195 | 195 |
Net Property & Equipment | 4 | 4 | 4 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 2 | 2 | 3 |
Total Assets | 87 | 137 | 171 | 201 | 201 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 12 | 15 | 12 | 8 | 4 |
Accounts Payable | 6 | 6 | 4 | 3 | 2 |
Current Portion Long-Term Debt | 3 | 3 | 2 | 2 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 19 | 23 | 18 | 18 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 36 | 43 | 41 | 31 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 81 | 93 | 95 | 98 | 100 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 18 | 18 | 18 | 18 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 134 | 154 | 154 | 146 | 144 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 599 | 594 | 589 | 585 | 555 |
Retained Earnings | -646 | -611 | -572 | -530 | -497 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -47 | -16 | 17 | 55 | 57 |
Total Liabilities & Shareholder's Equity | 87 | 137 | 171 | 201 | 201 |
Total Common Equity | -47 | -16 | 17 | 55 | 57 |
Shares Outstanding | 54.90 | 54.90 | 54.50 | 50.60 | 50.50 |
Book Value Per Share | -0.86 | -0.30 | 0.31 | 1.08 | 1.14 |